Novavax, Inc. (NVAX)
10.46
-0.14
(-1.32%)
USD |
NASDAQ |
Oct 02, 16:00
10.44
-0.02
(-0.19%)
After-Hours: 20:00
Novavax Net Income (Quarterly) : -53.39M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -53.39M |
| March 31, 2026 | -9.491M |
| December 31, 2025 | 17.53M |
| September 30, 2025 | -202.38M |
| June 30, 2025 | 106.51M |
| March 31, 2025 | 518.65M |
| December 31, 2024 | -81.03M |
| September 30, 2024 | -121.30M |
| June 30, 2024 | 162.38M |
| March 31, 2024 | -147.55M |
| December 31, 2023 | -178.39M |
| September 30, 2023 | -130.78M |
| June 30, 2023 | 58.01M |
| March 31, 2023 | -293.90M |
| December 31, 2022 | -182.25M |
| September 30, 2022 | -168.61M |
| June 30, 2022 | -510.48M |
| March 31, 2022 | 203.41M |
| December 31, 2021 | -846.28M |
| September 30, 2021 | -322.43M |
| June 30, 2021 | -352.32M |
| March 31, 2021 | -222.72M |
| December 31, 2020 | -177.56M |
| September 30, 2020 | -197.31M |
| June 30, 2020 | -17.52M |
| Date | Value |
|---|---|
| March 31, 2020 | -25.86M |
| December 31, 2019 | -31.83M |
| September 30, 2019 | -18.04M |
| June 30, 2019 | -39.60M |
| March 31, 2019 | -43.22M |
| December 31, 2018 | -49.33M |
| September 30, 2018 | -44.57M |
| June 30, 2018 | -44.49M |
| March 31, 2018 | -46.35M |
| December 31, 2017 | -50.84M |
| September 30, 2017 | -44.61M |
| June 30, 2017 | -44.46M |
| March 31, 2017 | -43.85M |
| December 31, 2016 | -57.11M |
| September 30, 2016 | -66.25M |
| June 30, 2016 | -79.35M |
| March 31, 2016 | -77.25M |
| December 31, 2015 | -78.81M |
| September 30, 2015 | -33.12M |
| June 30, 2015 | -20.64M |
| March 31, 2015 | -24.37M |
| December 31, 2014 | -31.55M |
| September 30, 2014 | -19.73M |
| June 30, 2014 | -17.86M |
| March 31, 2014 | -13.81M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Merck & Co., Inc. | -1.337B |
| Pfizer Inc. | -246.00M |
| Agenus, Inc. | -0.567M |
| Editas Medicine, Inc. | -18.23M |
| Recursion Pharmaceuticals, Inc. | -131.00M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 56.70M |
| Total Expenses (Quarterly) | 110.08M |
| EPS Diluted (Quarterly) | -0.3244 |
| Enterprise Value | 1.302B |
| Gross Profit Margin (Quarterly) | 77.70% |
| Profit Margin (Quarterly) | -94.16% |
| Earnings Yield | -14.56% |
| Normalized Earnings Yield | -8.780 |